Form 4: Bristol-Myers Squibb CEO Christopher Boerner Reports Stock Transactions

Christopher Boerner, CEO of Bristol-Myers Squibb, reports the vesting and disposal of market share units and shares for tax obligations.

Summary

• On November 1, 2024, Christopher Boerner, CEO of Bristol-Myers Squibb, reported transactions involving the company's common stock.
• These transactions included the vesting of 2,964 market share units, which converted into shares of common stock.
• A downward adjustment of 55 shares was made due to the performance factor associated with the market share units.
• 1,488 shares were withheld for payment of taxes upon the vesting of the awards at a price of $54.32 per share.
• Following these transactions, Boerner directly owns 102,626 shares of Bristol-Myers Squibb common stock and 8,894 market share units.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of executive stock transactions, with no indication of positive or negative sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are regularly reported to the SEC. These transactions can provide insights into management's perspective on the company's performance and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include market share units or similar equity-based awards to align management's interests with those of shareholders.
• Vesting schedules, such as the 25% annual vesting described in the document, are standard practice in the industry.
• Companies like Pfizer (PFE) and Johnson & Johnson (JNJ) also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The vesting of market share units aligns executive compensation with shareholder value.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates